Member Info for Laura2022

Please read Ironmohty km VAL seemingly that's difficult sincerely it is....AGAIN...from over 6 weeks ago VAL CEO Q and A

"We have every indication we will be able to put out a substantial update before the end of the year - if that wasn't the case then clearly we would have already announced that wasn't the case.. we have a good degree of certainty."

"When the sublicense is signed, we will then be able to invoice them (TheoremRX) for the time that has been spent under the service agreement.. along with the upfront payments and the early milestone payments"

Please read the VAL BB as I suggested you did 3 weeks ago

It's from the VAL CEOs own words at the Q and A

Looking forward to the people making the connection TO PYC

VAL (and therfore PYC) potentially leading this fight against prostate cancer and endometriosis

Great to see swines put in their pen

Surging now

Talk is deal to be sorted around 6th November

VAL up again

Thanks Stephen

And now,due to wider marker malaise ,at 1 4p it's only £1.83mln cap with c.£750k cash

Compared to most of AIM this is ridiculous undervalued when you think PYC could well achieve over £1mln revenues for year June 23 to 24 Judging by PYC own mews releases

I see you've not posted aince 2018 , welcome back to LSE

Any information Stephen is a Good poster who posted a summary of PYC about 4 weeks ago

Yes Iom they raised £390k in June and also had £400k in the bank ,as they are a software company their over heads are low , the £790k is good for the foreseeable future (see Sept 2023 annual report)

The potential £6mln( not all at once ) VAL201 could be nearing a conclusion in next few weeks (see VAL merger information which triggers the out licence of VAL201 which PYC gain from having done the modelling

The DoseMeRx USA deal potentially integrating PYC dosing tool Into a multi $mln US market

The personalised/A.I capabilities

The £1mln+ pipeline of pre-checked deals /contracts on top of the c £300k+ won since July 2023 (estimates )

The move into bio statistics

All for £1.9mln market value

A reminder how this positively impact PYC

Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection. ......... In recognition of the collaborative nature of this new agreement, Physiomics will also be offered a seat on the ValiRx scientific advisory board.

 

Dr Suzy Dilly, Chief Executive Officer of ValiRx, commented: "I am pleased to be able to expand our collaboration and the scope of work being carried out by Physiomics. Enhancing the scientific understanding of our results using cutting edge technology ensures we maximise the value of the data we have collected. This will help in the design and execution of future clinical trials and support discussions with potential new partners. We expect that outputs from the application of Physiomics' technology will be incorporated into scientific publications presenting the results from the VAL201 clinical trial."

Thank Stephen

I was wondering why it was dropping on very small sells

This explains it

And it looked like it was moving up into the end of Friday

Alzheimer test could be pivotal

Looking good here

Bio techs getting noticed

APTA finally broken 1 3p....Great to see

APTA VAL PYC

Even companies like FA. (Fiŕeangel) have been taken over for 200%+ premium today valuing FA at £28mln and they were in dire straight

So many hg premium small cap takeover approaches last 12mths

I think PYC has to worth multiples of current £2mln

Nice summary Acker

Would be useful if the person that bought 280k didn't then sell an hour later I 2 separate trades (200k and 80k)

Would be good to have investors who understand the long term potential

The potential £6mln( not all at once ) VAL201 could be nearing a conclusion in next few weeks (see VAL merger information which triggers the out licence of VAL201 which PYC gain from having done the modelling

The DoseMeRx USA deal potentially integrating PYC dosing tool Into a multi $mln US market

The personalised/A.I capabilities

The £1mln+ pipeline of pre-checked deals /contracts

The move into bio statistics

All for £1.9mln market value

From the recent Annual report

Staff

The Company continued to build its technical team with the addition of two highly qualified new scientists, chosen from among a strong field of applicants. The Company continues to attract significant interest from those who want to be involved at the cutting edge of cancer care and data modelling.

Staff utilisation rates are regularly reviewed as part of the Company's workforce planning process and the Company would like to thank all its staff for their continuing hard work and commitment during the year.

Outlook

The impact of the Company's strengthened Board is already being felt through the implementation of new marketing activities, collaborations such as with Inaphaea and Beyond Blood and through the proposed expansion of its consulting business into the field of biostatistics. The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.

Good morning Newgrange

Good call, its so undervalued here and it has been dragged down on small sells and tiny little trades per the last few days

Oman

Pyc appointed a very experiences industry veteran in on 3rd Oct he did a interview with PYC where he said

This is what Peter Sargent said in his PYC blog on 3rd Oct

Q: What opportunities do you see for the company?

A: “I think Physiomics certainly has an exciting future. The business has invested significantly in developing expertise and IP around its core modelling offering, with very positive client feedback and a high percentage of repeat business. With these solid foundations now built, I see an opportunity not only to scale the core business, but to build adjacent offerings in areas such as biostatistics and expand into new indications. Additionally, with continued development of our personalised medicine tools there is also the potential to significantly improve the health outcomes of cancer patients prescribed already marketed medicines